Ross Osborn
Stock Analyst at Cantor Fitzgerald
(2.04)
# 3,087
Out of 5,238 analysts
112
Total ratings
31.43%
Success rate
-1.62%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Maintains: Overweight | $11 → $13 | $6.83 | +90.34% | 4 | Nov 6, 2025 | |
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $16.16 | +98.02% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $2.37 | +279.75% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $107.94 | -11.99% | 2 | Aug 6, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $12.27 | +103.75% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $3.60 | +233.33% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $10.50 | +14.29% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $2.95 | +137.29% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.03 | +94.17% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $18.35 | -7.36% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $1.73 | +420.23% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $18.40 | +150.00% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $1.01 | +692.08% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $42.06 | -42.94% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $2.61 | +53.26% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $6.58 | +36.78% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $4.11 | +410.95% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $3.22 | +397.67% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.41 | +148.23% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $2.25 | +2,122.22% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $258 | $7.16 | +3,507.54% | 2 | Aug 18, 2023 |
CVRx, Inc.
Nov 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $6.83
Upside: +90.34%
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $16.16
Upside: +98.02%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $2.37
Upside: +279.75%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $107.94
Upside: -11.99%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $12.27
Upside: +103.75%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $3.60
Upside: +233.33%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $10.50
Upside: +14.29%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $2.95
Upside: +137.29%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.03
Upside: +94.17%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $18.35
Upside: -7.36%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $1.73
Upside: +420.23%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $18.40
Upside: +150.00%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.01
Upside: +692.08%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $42.06
Upside: -42.94%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $2.61
Upside: +53.26%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $6.58
Upside: +36.78%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $4.11
Upside: +410.95%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $3.22
Upside: +397.67%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.41
Upside: +148.23%
May 16, 2024
Reiterates: Overweight
Price Target: $50
Current: $2.25
Upside: +2,122.22%
Aug 18, 2023
Reiterates: Neutral
Price Target: $258
Current: $7.16
Upside: +3,507.54%